Alzheimer’s disease could soon be a distant memory.
A revolutionary new Alzheimer’s drug named lecanemab could mark a major breakthrough in the decades-long battle against the neurological disorder, according to eye-opening Phase 3 trials. The potentially game-changing dry runs transpired in May 2021, but the results were only published Tuesday in the New England Journal of Medicine.
“This first step is the hardest; I truly believe it represents the beginning of the end,” said Professor John Hardy, group leader at UK Dementia Research Institute at the University College London, describing the promising findings.
Comments are closed.